Live vaccines—a short‐cut to cancer viro‐immunotherapy. Issue 1 (20th November 2019)

• Record Type: Journal Article
• Authors: Wirth, Thomas C; Niemann, Julia; Kühnel, Florian
• Is Part Of: EMBO molecular medicine. Volume 12:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-11-20
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201911496
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract : Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular Medicine, Aznar et al present the already approved yellow fever vaccine 17D as an oncolytic agent for tumour immunoactivation. In tumour‐bearing mice, they demonstrated a convincing synergy of the vaccine with CD137 agonistic antibodies resulting in significantly improved survival. Abstract : In this Issue of EMBO Molecular Medicine, Aznar et al demonstrate the therapeutic potential of the already approved yellow fever vaccine 17D for viro‐immunotherapy of cancer.